Abivax shares climbed sharply after updated data from its Phase 3 ulcerative colitis (UC) program, helping the company’s stock rebound following earlier safety-related volatility around obefazimod. In the ABTECT Maintenance Part 2 supplemental analysis, Abivax said induction nonresponders achieved clinical remission in 37.2% and endoscopic remission in 34.5% at Week 44 with continued 50 mg dosing. The company also reported dose-escalation results in patients who relapsed during Part 1, aiming to show that remission can be recaptured over time. The story notes that malignancy disclosures earlier in the month did not generate new safety signals in this later analysis, with the incidence rates (adjusted for patient-year exposure) described as within pre-defined background ranges. Still, investors will likely weigh durability of benefit and ongoing malignancy surveillance as obefazimod development proceeds.